Results 301 to 310 of about 6,274,440 (386)

THE METABOLISM OF THIOCYANATE IN THE RAT AND ITS INHIBITION BY PROPYLTHIOURACIL

, 1949
John L. Wood, Edward F. Williams
openalex   +1 more source

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

CD44 Marks Dormant Tumor Cells After HER2 Inhibition in Breast Cancer Cells. [PDF]

Int J Mol Sci
Vargas C, Aguirre-Ducler A, Cereceda K, Quijada S, Escobar-Gómez N, Castillo RL, Escobar-Aguirre M.   +6 more
europepmc   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Complement System Inhibitors in Nephrology: An Update-Narrative Review. [PDF]

Int J Mol Sci
Apetrii M, Costache AD, Costache Enache II, Voroneanu L, Covic AS, Kanbay M, Covic A.   +6 more
europepmc   +1 more source

Nicotinamide Inhibition of Tri- and Diphosphopyridine Nucleotide-Linked Dehydrogenases

, 1952
Spyridon G.A. Alivisatos, Orville F. Denstedt   +1 more
openalex   +1 more source

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

Molecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez, Asieh Naderi, Kim‐Tuyen Huynh‐Dam, Vitali Sikirzhytski, Ioulia Chatzistamou, Hippokratis Kiaris   +5 more
wiley   +1 more source

Antimicrobial, Time-Kill Kinetics, and Biofilm Inhibition Properties of <i>Diospyros lycioides</i> Chewing Stick Used in Namibia Against <i>Enterococcus faecalis</i>. [PDF]

J Trop Med
Shatri AMN, Bere SK, Bouman D, Mumbengegwi DR.   +3 more
europepmc   +1 more source

Small modifier, big decision: switching to SUMO mode adds weight to cancer stemness in mammary tumors

Molecular Oncology, EarlyView.
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley   +1 more source

Cardiovascular Outcomes of Perioperative Sodium-Glucose Transporter 2 Inhibition in Cardiac Surgery Patients: An Open-Label Randomized Pilot Study. [PDF]

Acta Anaesthesiol Scand
Snel LIP, Oosterom-Eijmael MJP, Lankadeva YR, Plummer MP, Preckel B, Zuurbier CJ, Hermanides J, van Raalte DH, Hulst AH.   +8 more
europepmc   +1 more source